Overcome bottlenecks in viral vector manufacturing

The success of your gene therapy vectors is dependent on optimal formulation conditions. Finding a buffer that provides better long-term stability for AAVs is a crucial step in the process of developing a clinic-bound therapeutic. Join Dr. Igor Oruetexebarria, senior scientist at Kuopio Center for Gene and Cell Therapy, as he walks through some of the current challenges in the field of gene therapy AAV development, and explains how the nanoDSF and DLS capabilities of the Prometheus Panta have improved the outcomes for his vector candidates.

Previous Article
NanoTemper Technologies arms gene therapy scientists with Static Light Scattering to sharpen their tool kit for development of AAVs
NanoTemper Technologies arms gene therapy scientists with Static Light Scattering to sharpen their tool kit for development of AAVs

SOUTH SAN FRANCISCO, Calif Feb 16 2022 — NanoTemper Technologies today announced the addition of Static Lig...

Up next
How to improve outcomes of your viral vectors for gene therapy with high-quality data from biophysical profiling methods
How to improve outcomes of your viral vectors for gene therapy with high-quality data from biophysical profiling methods

Optimizing your vectors for gene therapy is a daunting task. When developing and optimizing AAVs, concerns ...

[New] Prometheus Panta with SLS

Build effective AAV vectors for gene therapy with
high-quality stability profiling data

Learn more